BioRestorative Therapies Inc. (NASDAQ: BRTX), a clinical-stage company specializing in stem cell-based therapies, hopes to provide better treatment options for the millions of Americans who do not want to take opioids, have struggled with addiction, or want better care. <br /><br />BioRestorative’s leading product and novel drug BRTX-100 is an autologous stem cell product that uses the patient’s stem cells, which are harvested, cultured, and then injected directly into the patient’s body. BRTX-100 is a non-invasive treatment – the procedure is a single intra-discal injection that takes approximately 20 minutes. This product is currently being used in BioRestorative’s ongoing phase 2 clinical trial.
